Company intelligence / Profile preview

BGC

Grants, New Mexico, USA

Ownership: Private
Development stage: Other

Overview

BGC, with the Alterola portfolio, aims to be the largest pharmaceutical cannabinoid botanical development company, focusing on therapeutic candidates derived from cannabinoids and botanical sources; recent acquisition brought >200 molecules into its pipeline.

Therapeutic areas: ImmunologyRare DiseasesOtherOncologyNeurology
Modalities: Small moleculeCannabinoid-based therapyBotanical drug
Industry: Biotech

Beyond the preview

Go deeper on BGC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGC.

Explore the full profile